Consolidated Statements of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:
Net income	$ 15,042	$ 3,141
Adjustments to reconcile to net cash provided by (used in) operating activities:
Stock-based compensation expense	8,459	8,417
Depreciation and amortization	13,547	7,679
Current and deferred income taxes	4,667	8,679
Non-cash development expenses from joint venture	(348)	3,163
Impairment of in-process research and development	0	9,600
Change in fair value of contingent value rights	0	(3,005)
Change in fair value of contingent purchase consideration	349	0
Excess tax benefits from stock-based compensation	(1,949)	(1,482)
Other	(19)	(39)
Changes in operating assets and liabilities:
Accounts receivable	65,950	57,006
Inventories	(1,164)	(3,584)
Income taxes	(6,927)	(1,597)
Prepaid expenses and other assets	(3,532)	(1,544)
Accounts payable	(1,622)	(3,495)
Accrued expenses and other liabilities	(240)	301
Accrued compensation	(4,164)	(4,790)
Deferred revenue	278	212
Net cash provided by operating activities	88,327	78,662
Cash flows from investing activities:
Purchases of property, plant and equipment	(34,420)	(40,943)
Proceeds from sale of assets	0	11,765
Proceeds from maturity of investments	0	1,966
Acquisition of Healthcare Protective Products Division	(24,120)	0
Net cash used in investing activities	(58,540)	(27,212)
Cash flows from financing activities:
Proceeds from borrowings on long-term indebtedness	0	12,946
Issuance of common stock subject to employee equity plans	2,505	495
Excess tax benefits from stock-based compensation	1,949	1,482
Principal payments on long-term indebtedness	(3,352)	(9,386)
Contingent value right payment	0	(1,748)
Purchase of treasury stock	0	(1,457)
Restricted cash	0	220
Net cash provided by financing activities	1,102	2,552
Effect of exchange rate changes on cash and cash equivalents	6	(2)
Net increase (decrease) in cash and cash equivalents	30,895	54,000
Cash and cash equivalents at beginning of period	141,666	143,901
Cash and cash equivalents at end of period	$ 172,561	$ 197,901